Eurobio-Scientific SA (ALERS) AI Stock Analysis

1 Followers

Eurobio-Scientific SA

(Paris:ALERS)

Select Model

Rating:57Neutral

Price Target:EUR 26.00▼(-1.33% Downside)

Action:reiterated

Date:09/18/26

Financial performance drives the score through balance sheet stability and positive cash flows despite revenue volatility; supportive technical trends add lift while high valuation caps upside.

Positive Factors

Conservative LeverageDebt-to-equity of about 0.09 and a sizable equity buffer indicate conservative financing. This reduces balance-sheet strain and preserves flexibility to fund product development, distribution expansion, or working-capital needs through the next several quarters.

Negative Factors

Lower Margin DurabilityNet margin of about 2.9% in 2025, versus exceptionally high levels in 2021–2022, shows earnings power has reset lower. Even with gross margin around 40–46%, thinner operating profitability leaves less room to absorb execution pressure or reinvest.

Eurobio-Scientific SA (ALERS) vs. iShares MSCI France ETF (EWQ)

Market Cap: EUR 258.89M
Dividend Yield: ―
Average Volume (3M): 3,896
Price to Earnings (P/E): 37.6
Beta (1Y): 0.24
Revenue Growth: 6.28%
EPS Growth: 204.56%
Country: France
Employees: 443
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Eurobio-Scientific SA Business Overview & Revenue Model

Company Description

Eurobio Scientific S.A. specializes in the conceptualization, development, and distribution of sophisticated diagnostic products. Its key therapeutic and research domains include transplantation, infectious illnesses, life sciences, and oncology. The...

How the Company Makes Money

Eurobio Scientific makes money primarily by selling products and services used by laboratories for clinical testing and life-science research. Key revenue streams include: (1) Sales of in-vitro diagnostic products: revenue from commercializing IVD as...

Eurobio-Scientific SA Financial Statement Overview

Summary

Mixed results with post-COVID revenue volatility and compressed margins offset by strengthened balance sheet, low debt, and consistently positive cash flows.

Income Statement

45Neutral

Balance Sheet

75Positive

Cash Flow

55Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	172.00M	169.00M	154.95M	130.65M	152.61M	184.71M
Gross Profit	75.43M	68.40M	71.95M	57.49M	65.04M	97.44M
EBITDA	35.13M	32.39M	29.05M	24.55M	40.20M	79.63M
Net Income	7.24M	4.87M	4.00M	4.83M	24.94M	60.54M
Balance Sheet
Total Assets	427.08M	256.76M	257.17M	316.33M	330.42M	209.22M
Cash, Cash Equivalents and Short-Term Investments	26.34M	20.66M	23.07M	89.03M	85.94M	102.39M
Total Debt	14.74M	16.02M	34.05M	100.66M	113.60M	15.68M
Total Liabilities	239.12M	72.83M	78.31M	141.16M	157.75M	49.00M
Stockholders Equity	187.96M	183.92M	178.85M	175.17M	172.34M	159.91M
Cash Flow
Free Cash Flow	5.05M	6.28M	13.45M	22.71M	39.01M	63.61M
Operating Cash Flow	19.67M	18.85M	16.70M	26.77M	41.85M	65.46M
Investing Cash Flow	-164.23M	-12.89M	-10.74M	-318.00K	-141.76M	-5.47M
Financing Cash Flow	143.04M	-8.16M	-72.09M	-23.50M	82.31M	-23.75M

Eurobio-Scientific SA Technical Analysis

Technical Analysis SentimentPositive

Last Price26.35

Price Trends

50DMA24.40Positive

100DMA22.65Positive

200DMA22.71Positive

Market Momentum

MACD0.53Positive

RSI80.97Negative

STOCH20.00Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALERS, the sentiment is Positive. The current price of 26.35 is above the 20-day moving average (MA) of 25.90, above the 50-day MA of 24.40, and above the 200-day MA of 22.71, indicating a bullish trend. The MACD of 0.53 indicates Positive momentum. The RSI at 80.97 is Negative, neither overbought nor oversold. The STOCH value of 20.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALERS.

Eurobio-Scientific SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

FR:ALERS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FR:ALERS	57Neutral	EUR 258.89M	37.64	3.89%	―	6.28%	204.56%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:ALIKO	46Neutral	EUR 22.26M	-5.31	-22.49%	―	37.28%	7.83%
FR:ALNOV	45Neutral	EUR 31.94M	-0.75	-159.70%	―	10.36%	29.41%
FR:ALMDT	43Neutral	EUR 194.08M	-3.46	271.64%	―	2.16%	-5.26%
FR:ALMKT	40Underperform	EUR 18.53M	1.46	-157.72%	―	3.38%	―

* Healthcare Sector Average

Performance Comparison

FR:ALERS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
FR:ALERS	Eurobio-Scientific SA	26.35	1.90	7.77%
FR:ALMKT	MAUNA KEA TECHNOLOGIES	0.09	0.01	5.75%
FR:ALNOV	Novacyt S.A.	0.43	-0.01	-1.15%
FR:ALDMS	Diagnostic Medical Systems	0.90	-0.40	-30.77%
FR:ALIKO	Ikonisys SA	1.45	-0.01	-0.68%
FR:ALMDT	Median Technologies	4.25	1.17	38.15%

Eurobio-Scientific SA Corporate Events

EB Development moves toward full takeover and potential delisting of Eurobio Scientific

Sep 16, 2026

EB Development, the majority shareholder of Eurobio Scientific, plans to file a public buyout offer followed by a compulsory buyout at €25.30 per share, matching the price of its 2024 tender bid. The proposed offer implies significant premiums over r...

Eurobio Scientific lifts H1 revenue as proprietary and international sales drive strategic shift

Jul 28, 2026

Eurobio Scientific reported a 5% rise in first-half 2026 revenue to €84.5 million, with proprietary products growing 10% to €31.3 million and now accounting for 37% of sales, while international revenues reached 47%. Overall growth was largely driven...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 18, 2026

Eurobio-Scientific SA AI Stock Analysis